International legal practice Osborne Clarke has advised Breath Therapeutics in the EUR 43.5 million Series A financing round co-led by Gimv and Sofinnova Partners and joined by Gilde Healthcare.

Breath Therapeutics, a spin-off of PARI Pharma, develops advanced drug-aerosol therapeutics in pulmonary orphan indications. The funding will enable the company to conduct Phase III trials in Europe and the US, submit for marketing approval and prepare for commercialization.

The Osborne Clarke Netherlands team was led by Partner Herke van Hulst, who was assisted by Senior Associate Geoffrey Beurskens and Associate Niels Dolk.

 

Follow
Corporate communications and press contacts
If you are a journalist and would like comment or background from our legal experts, we can help. Our team will put you in touch with the best person. View a full list of our international press contacts by jurisdiction here.

Connect with one of our experts